ArticleScientific reports2026
Functional characterization of fungal endophytes with antagonistic and plant growth-promoting activities in maize.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal endophytes play a crucial role in plant-microbe interactions by asymptomatically colonizing host tissues, enhancing plant growth, and providing defense. In the present study, three distinct endophytic fungi, namely Fusarium oxysporum CJR-1 (GenBank Accession No. PZ477045), Penicillium sp. CJR-2 (GenBank Accession No. PZ477429) and Aspergillus cf. terreus CJR-4 (GenBank Accession No. PZ477430) were isolated from Crotalaria juncea L. plants and evaluated for antagonistic activity against phytopathogenic fungi and growth promotion in maize. Among the isolates, CJR-4 showed potent antagonistic activity against both tested phytopathogens, inhibiting the mycelial growth of Fusarium oxysporum (ITCC Accession No. 8111) and Alternaria alternata (ITCC Accession No. 1434) by 72.41 ± 5.02% and 68.31 ± 1.53%. On the other hand, isolate CJR-1 showed the highest mycelial inhibition of 74.60 ± 2.06% against A. alternata. Ethyl acetate crude metabolites of CJR-4 exhibited potent antifungal activity, with the highest zone of inhibition observed against A. alternata (21.66 ± 1.52 mm), followed by F. oxysporum (15.33 ± 1.15 mm) at 150 µL of tested concentration. GC-MS analysis of the ethyl acetate extract of CJR-4 revealed numerous bioactive metabolites, including diphenyl sulphone and 2-nonen-1-ol, which may contribute to its antifungal activity. In addition, 1-methylene-1H-indene and ethanone, 2-(formyloxy)-1-phenyl-, may be associated with antioxidant activity, as evidenced by potent DPPH (80.09 ± 0.11%) and ABTS (92.66 ± 0.17%) scavenging activities. Evaluation of PGP traits showed that CJR-1 produced the highest levels of indole-3-acetic acid (IAA) as 305.69 ± 0.41 µg mL⁻
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.